The Role of ATP-Binding Cassette Transporters in Neuro-Inflammation: Relevance for Bioactive Lipids by Gijs Kooij et al.
MINI REVIEW ARTICLE
published: 30 April 2012
doi: 10.3389/fphar.2012.00074
The role of ATP-binding cassette transporters in
neuro-inﬂammation: relevance for bioactive lipids
Gijs Kooij 1, Jack van Horssen1,VeeraVenkata Ratnam Bandaru2, Norman J. Haughey 2,3 and
Helga E. deVries1*
1 Blood-Brain Barrier Research Group, Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, Netherlands
2 Division of Neuroimmunology and Neurological Infections, Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
3 Division of Neuroimmunology and Neurological Infections, Department of Psychiatry, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Edited by:
Joana A. Palha, University of Minho,
Portugal
Reviewed by:
Muzamil Ahmad, Indian Institute of
Integrative Medicine, India
Raja S. Settivari, The Dow Chemical
Company, USA
*Correspondence:
Helga E. de Vries, Blood-Brain Barrier
Research Group, Department of
Molecular Cell Biology and
Immunology, VU University Medical
Center, P.O. Box 7057, 1007 MB
Amsterdam, Netherlands.
e-mail: he.devries@vumc.nl
ATP-binding cassette (ABC) transporters are highly expressed by brain endothelial cells
that form the blood–brain barrier (BBB).These efﬂux pumps play an important role in main-
taining brain homeostasis as they actively hinder the entry of unwanted blood-derived
compounds into the central nervous system (CNS). Consequently, their high activity at
the BBB has been a major hurdle for the treatment of several brain diseases, as they
prevent numerous drugs to reach their site of action within the brain. Importantly, recent
data indicate that endogenous substrates for ABC transporters may include inﬂamma-
tory mediators, such as prostaglandins, leukotrienes, cytokines, chemokines, and bioactive
lipids, suggesting a potential role for ABC transporters in immunological responses, and
more speciﬁcally in inﬂammatory brain disorders, such as multiple sclerosis (MS). In this
review, we will give a comprehensive overview of recent ﬁndings that illustrate this novel
role for ABC transporters in neuro-inﬂammatory processes. Moreover, we will provide
ﬁrst insights into underlying mechanisms and focus on the importance for bioactive lipids,
in particular platelet-activating factor, herein. A thorough understanding of these events
may form the basis for the development for selective treatment modalities to dampen the
neuro-inﬂammatory attack in MS and thereby reducing tissue damage.
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ABC TRANSPORTERS AT THE BLOOD–BRAIN BARRIER
Theblood–brainbarrier (BBB)protects the central nervous system
(CNS) from the entry of unwanted compounds and leukocytes,
thereby maintaining brain homeostasis. However, during neuro-
inﬂammatory diseases like multiple sclerosis (MS), immune cells
traverse the endothelial barrier and accumulate within the brain
parenchyma where they cause extensive tissue damage leading
to neurological deﬁcits (Frohman et al., 2006; Comabella and
Khoury, 2012). The BBB is in essence formed by specialized brain
endothelial cells, however surrounding cells, like astrocytes and
pericytes also play a key role in maintenance of barrier features
(Abbott et al., 2006). Next to the presence of complex tight junc-
tions, barrier properties of the BBB are instated by the presence
of speciﬁc endothelial ATP-binding cassette (ABC) transporters,
which actively remove unwanted compounds from the brain. The
ABC transporter family consists of a variety of efﬂux pumps
(Loscher and Potschka, 2005a), of which a few are generally
regarded as key BBB transporters, including P-glycoprotein (P-
gp), breast-cancer resistance protein (BCRP), and the multi-drug
Abbreviations:ABC,ATP-binding cassette; BBB,blood–brain barrier; BCRP,breast-
cancer resistance protein; CCL2: chemokine (C–C motif) ligand 2; CNS, central
nervous system; EAE, experimental autoimmune encephalomyelitis; MDR, multi-
drug resistance; MRP, multi-drug resistance-associated protein; MS, multiple scle-
rosis; PAF, platelet-activating factor; PAFR, platelet-activating factor receptor; P-gp,
P-glycoprotein.
resistance-associated proteins-1 and -2 (MRP-1, -2). In general,
ABC transporters drive cellular exclusion of a variety of exoge-
nous compounds and drugs through the cell membrane against
a concentration gradient at the cost of ATP hydrolysis (Loscher
and Potschka, 2005b). Expression and function of these trans-
porters can be regulated by a broad variety of endogenous and
exogenous factors, including nuclear receptors like steroid and
xenobiotic receptors (Loscher and Potschka, 2005b) or a variety of
inﬂammatory molecules (see review Miller, 2010).
ABC TRANSPORTERS AND NEURO-INFLAMMATION
Most data on the function of ABC transporters originates from
oncology research and is based on their capacity to cause multi-
drug resistance (MDR;Lage,2008). Todate, evidence is accumulat-
ing that ABC transporters may also contribute to immunological
processes based on their expression on various immune cells like
antigen presenting cells (Randolph et al., 1998; van de Ven et al.,
2006) and their potential to secrete inﬂammatory molecules like
leukotrienes and prostaglandins (see review van de Ven et al.,
2009). Together with their high expression on the BBB,ABC trans-
porters may modulate inﬂammatory processes that occur in CNS
disorders, including MS, a chronic inﬂammatory disorder of the
CNS leading to severe neurological deﬁcits. Pathologically, active
MS lesions contain abundant cellular inﬁltrates,whichmainly con-
sist of T-cells and macrophages with a foamy appearance (Bruck
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et al., 1996). The latter acquire their distinctive morphology by
ingestion and accumulation of vast amounts of myelin-derived
lipids and cellular debris. Foamy macrophages originate from
both resident microglia and inﬁltrating monocytes (Li et al., 1996)
and are thought to contribute to myelin sheaths damage, result-
ing in neuronal dysfunction. In the course of lesion progression,
enlarged proliferative astrocytes become the most predominant
cell type. These reactive astrocytes secrete neurotrophic factors for
neuronal survival, but also contribute to pathology by producing
pro-inﬂammatory cytokines and chemokines (Tani et al., 1996;
Speth et al., 2005; Sofroniew, 2009), which subsequently attract
leukocytes into MS lesions.
ATP-binding cassette transporters have been implicated in
various neurological disorders, including Alzheimer’s disease
(Vogelgesang et al., 2002),HIV encephalitis (Langford et al., 2004),
Parkinson’s disease (Bartels et al., 2008), and epilepsy (Sisodiya
et al., 2002; Aronica et al., 2011). However, as these disorders
lack a profound inﬂammatory component, the potential involve-
ment for ABC transporters in neuro-inﬂammation has been long
overseen. Conversely, we recently identiﬁed an important role for
ABC transporters in neuro-inﬂammatory processes underlying
MS pathogenesis (Kooij et al., 2009, 2010, 2011).We demonstrated
that P-gp, MRP-1, and -2 are absent on healthy brain astrocytes,
but their expression is highly increased on reactive astrocytes
in MS lesions. In contrast, the expression of P-gp on endothe-
lial cells of the BBB was slightly reduced in active lesions (Kooij
et al., 2010), whereas the expression of endothelial BCRP, MRP-1
and -2 remained unaffected. Moreover, we showed that the astro-
cytic ABC transporters P-gp and MRP-1 mediated the secretion of
chemokine (C–C motif) ligand 2 (CCL2), which in turn promotes
immune cellmigration in an in vitro model of the BBB (Kooij et al.,
2011). In vivo evidence supporting a role for P-gp in immunomod-
ulation was obtained using animals that lack P-gp (mdr1a/1b−/−
animals), as they experience a signiﬁcant reduction in clinical
symptoms of experimental autoimmune encephalomyelitis (EAE;
Kooij et al., 2009), a validated animal model for MS. Overall, these
results strengthen the hypothesis that in addition to exporting
unwanted compounds from cells, ABC transporters can actively
interfere in immune processes by secreting inﬂammatory mol-
ecules, thereby illustrating a novel (patho)physiological role for
these transporters in neuro-inﬂammatory disorders.
BIOACTIVE LIPIDS
A controversial issue remains whether ABC transporters them-
selves are capable to transport inﬂammatory molecules as sug-
gested by some groups (Gsur et al., 1996; Frank et al., 2001) or that
ABC transporters mediate the secretion of other relevant physi-
ological substrates, such as bioactive lipids (Raggers et al., 2001)
that in turn affect cytokine secretion as a secondary effect (Huang
et al., 1999). The latter seems plausible as a large group of ABC
transporter substrates have a lipophilic nature (Lagas et al., 2008).
To date, the ABC transporter mediated secretome of endogenous
molecules remains to be determined, but likely include various
bioactive lipids, which are known to regulate a variety of cellu-
lar signaling events through biophysical interactions with proteins
that modify location, scaffolding, and signal transduction (Wieg-
mann et al., 1994; Ballou et al., 1996; Bradshaw et al., 1996;
dam-Klages et al., 1998; Kronke, 1999). For example, rapid and
transient alterations in the ceramide content of neuronal mem-
branes have been shown to regulate neuronal excitability, synaptic
transmitter release, plasma membrane insertion, and removal of
transmembrane receptors (Inokuchi et al., 1997; Rohrbough et al.,
2004; Kajimoto et al., 2007; Wheeler et al., 2009; Norman et al.,
2010). Similarly, ceramide metabolism has been shown to direct
immune activation through regulating the formation and func-
tion of the immunological synapse, T-cell activation, and cell
death (Ballou et al., 1996; D’Souza et al., 1996; Solomon et al.,
2003; Falcone et al., 2004; Detre et al., 2006). Other lipids such as
sphingosine-1-phosphate, prostaglandins, arachidonic acid, and
platelet-activating factor (PAF) act directly as second messengers.
Many of these lipid metabolites are released from cells and act as
ligands to regulate function through speciﬁc receptor interactions.
Although many of these lipid metabolites are released from cells
in a regulated manner, the exact underlying mechanisms are cur-
rently not well deﬁned. Understanding how these lipid-derived
second messengers are exported from cells will further increase
our understanding of immune regulation and could identify spe-
ciﬁc therapeutic targets to dampen aberrant immune function in
disease settings such as MS.
MECHANISM OF ACTION: PLATELET-ACTIVATING FACTOR
Although the etiology of MS remains elusive, a crucial role has been
established for the immune system, including a broad repertoire
of inﬂammatory agents (Steinman, 2001; Hohlfeld and Wekerle,
2004; Comabella and Khoury, 2012). One of these agents is PAF,
a potent pro-inﬂammatory phospholipid mediator with a wide
range of biological activities (Stafforini et al., 2003). Several lines
of evidence suggest a potential role for PAF in MS and EAE patho-
genesis (Desai and Barton, 1990; Pedotti et al., 2003). Bioactivities
of PAF are elicited by binding to the PAF receptor (PAFR), which
belongs to the family of G-protein-coupled receptors (Honda
et al., 1991). Interestingly, animals that lack the PAFR displayed
lower incidence of disease and less severe clinical symptoms in
the chronic phase of EAE compared to control mice (Kihara
et al., 2005). Strikingly, no differences were observed in peripheral
immune parameters that are associated with EAE, highlighting
an important role for the PAFR in the neuropathology of EAE.
Importantly, it has been demonstrated that PAF levels are elevated
in the cerebrospinal ﬂuid and plasma of MS patients (Callea et al.,
1999). Together, these ﬁndings suggest that PAF likely contributes
to MS pathogenesis; however, its cellular source in the CNS is yet
unknown and data on the expression of PAFR in MS brain tissue
remains elusive.
To ﬁrst gain insight into the PAFR expression proﬁle we per-
formed a comprehensive immunohistochemical analysis to exam-
ine the distribution pattern of PAFR in various MS lesion stages.
Classiﬁcation of MS lesions was based on standard immuno-
histochemical analysis for myelin (proteolipid protein, PLP,
Figure 1A). Active demyelination was demonstrated by the pres-
ence of phagocytic perivascular and parenchymal macrophages
containing myelin degradation products (Figure 1A, insert) as
described previously (van der Valk and De Groot, 2000; van
Horssen et al., 2006a,b). In white matter from non-neurological
control brain tissue (data not shown) and normal appearing
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FIGURE 1 | Platelet-activating factor receptor (PAFR) expression in active
MS lesions. (A) Active MS lesions are characterized by a loss of myelin
(proteolipid protein, PLP), which is ingested by foamy macrophages (insert).
(B) In normal appearing white matter (NAWM), PAFR expression was mainly
restricted to glial cells (arrowheads). (C) In active lesions PAFR
immunostaining was intense in reactive astrocytes (arrowhead) and foamy
macrophages (arrows). Co-localization of PAFR immunoreactivity (green) with
CD68 (D) and GFAP (E) immunoreactivity (in red) conﬁrms the morphological
observations. Original magniﬁcation: (A) 20×, (B,C) 200×, (D,E) 250×. PAF
C16:0 levels were determined in supernatants and cell pellets derived from
primary human reactive astrocytes from MS lesions using liquid
chromatography electro spray ionization mass spectrometry (LC/ESI/MS/MS).
P-gp inhibition reduced PAF secretion from reactive astrocytes (F), whereas
intracellular levels were increased (G). *p<0.05 by Student’s t -test.
white matter (NAWM) PAFR (Figure 1B) immunoreactivity was
mainly restricted to glial cells (arrowheads). In active demyelinat-
ing lesions (Figure 1C) abundant PAFR staining was observed in
foamy macrophages (arrows) and hypertrophic astrocytes (arrow-
head), whereas endothelial cells only weakly express PAFR. In
chronic inactive MS lesions, PAFR was consistently upregulated
in reactive astrocytes (data not shown). Using double immunoﬂu-
orescence analysis we conﬁrmed the cellular localization of PAFR
in active MS lesions and showed that it is expressed by CD86-
positive macrophages (Figure 1D) and GFAP-positive astrocytes
(Figure 1E). These results are in line with microarray data show-
ing increased levels of PAFR transcripts in MS lesions (Lock et al.,
2002), but illustrate for the ﬁrst time the cellular origin of PAFR.
Kihara and co-workers (Kihara et al., 2005) have shown that
binding of PAF to its receptor increases the phagocytic activity
of macrophages, a process that may likely occur in MS lesion
development. However, the cellular source of PAF in the CNS
during neuro-inﬂammation is to date unknown.
In general, PAF is produced by a variety of cells, including
neutrophils, eosinophils, monocytes, macrophages, and vascular
endothelial cells (Montrucchio et al., 2000). Although it is cur-
rently unknownhowPAF is secreted from these cells, an important
role has been suggested for ABC transporters like P-gp (Rag-
gers et al., 2001). Our ﬁndings suggest an important role for
P-gp on reactive astrocytes, as P-gp expression and function are
highly increased early in the course of MS lesion formation (Kooij
et al., 2011). Astrocytic P-gp may mediate the release of leuko-
cyte attracting chemokines, a process that might be mediated by
PAF. We isolated human primary reactive astrocytes directly from
active MS lesions (as described previously by De Groot et al., 1997;
Elkord et al., 2005) and cultured them in the presence or absence
of the speciﬁc P-gp inhibitor reversin 121 for 6 h. Supernatants
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FIGURE 2 | ATP-binding cassette (ABC) transporters at the BBB in health
and disease.The BBB is formed by brain endothelial cells, instated by
astrocyte endfeet and pericytes (P) and surrounded by perivascular
macrophages (PVM). Under normal conditions, astrocytes only marginally
express ABC transporters. In diseased state, leukocytes (L) adhere to brain
EC via cell adhesion molecules (CAMs), which in turn lead to transmigration
of these cells into the CNS where they cause tissue damage. Our preliminary
data indicate that reactive astrocytes highly increase their ABC transporter
expression and function, which may result in increased efﬂux of inﬂammatory
mediators (IM). These molecules in turn may (1) increase endothelial CAM
expression and subsequent leukocyte adhesion and (2) stimulate leukocyte
attraction into the CNS via chemokine secretion. In that way, ABC
transporters can regulate leukocyte migration into the CNS at various cellular
levels, thereby contributing to tissue damage in MS.
and cell pellets were harvested and PAF C16:0 levels were deter-
mined using liquid chromatography electro spray ionization mass
spectrometry (LC/ESI/MS/MS;Wheeler et al., 2008). Notably, PAF
secretion was signiﬁcantly reduced in the presence of P-gp inhi-
bition, whereas intracellular levels were increased (Figures 1F,G).
These data strongly suggest a direct role for P-gp in the release
of PAF form reactive astrocytes, and provide the ﬁrst mechanistic
insights in the role of bioactive lipids and ABC transporters in MS
lesion formation.
FUTURE PERSPECTIVES
Over the last decade, a novel role for ABC transporters in reg-
ulating immune responses is emerging. These new ﬁndings are
challenging the current view of ABC transporters as gatekeep-
ers of the BBB, but instead indicate that these transporters are
able to contribute to degenerative and inﬂammatory responses
under pathological conditions (Figure 2, model). Hence, further
research is warranted to gain insight into the ABC transporter
secretome under normal and inﬂammatory conditions to deﬁne
a set of bioactive lipids that regulate the release of inﬂamma-
tory mediators from cells. Moreover, future experiments need
to deﬁne the exact mechanisms by which bioactive lipids induce
cytokine/chemokine release from cells, or if they act as chemoat-
tractants themselves (i.e., G-protein-coupled PAFR has many sim-
ilarities with chemokine receptors). From a therapeutical point of
view, targeting cell-speciﬁc ABC transporter substrates may be an
attractive approach to dampen inﬂammation, as systemic inhibi-
tion of ABC transporters will likely cause major side effects. Next
to that, more research is warranted to delineate the contribution
of bioactive lipids in immune responses and neuro-inﬂammatory
diseases like MS, using speciﬁc knock-out animals and/or selec-
tive inhibitors. Ultimately, this will open new therapeutic avenues
to limit the neuro-inﬂammatory attack and prevent brain tissue
damage.
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